evidence from San Antonio Breast Cancer Symposium supporting a small but real advantage for bisphosphonates in improving outcome for post menopausal women with hormone-driven breast cancer. This probably is through reduction in the development of bone metastases.
It is unclear whether potent intermittent intravenous zoledronic acid is to be preferred over potentially weaker oral agents commonly used in osteoporosis such as risedronate and alendronate.
